Want to see AU:IME full AI Analyst Report?
Top Page
ImExHS Limited
(Sydney:IME)
Select Model
Select Model
Rating:52Neutral
Price Target:
AU$0.36
▼(-10.25% Downside)
Action:Reiterated
Date:08/05/26
The score is driven primarily by mixed fundamentals: improving revenue growth and a turnaround to positive operating/free cash flow support the outlook, and the low-debt balance sheet reduces financial risk. These positives are weighed down by persistent losses, negative margins/ROE, and a significant drop in gross margin. Technically, the stock remains in a weak trend (below major moving averages with negative MACD), and valuation is constrained by negative earnings and no stated dividend yield.
Positive Factors
Accelerating Revenue Growth
Revenue growth accelerated materially in 2025 after a weak prior year, indicating improving commercial traction and broader business activity. If sustained, this expansion can support operating leverage, provide resources for reinvestment, and strengthen the company’s position in medical diagnostics and research.
Negative Factors
Persistent Operating Losses
Ongoing net losses and a negative operating margin show that revenue growth has not yet translated into sustainable profitability. This weakens retained capital generation, limits the benefits of scale, and leaves the business dependent on execution improvements before earnings can become durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
Revenue growth accelerated materially in 2025 after a weak prior year, indicating improving commercial traction and broader business activity. If sustained, this expansion can support operating leverage, provide resources for reinvestment, and strengthen the company’s position in medical diagnostics and research.
Read all positive factors
ImExHS Limited (IME) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$17.68M
Dividend YieldN/A
Average Volume (3M)6.07K
Price to Earnings (P/E)92.9
Beta (1Y)0.40
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees290
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)<0.01
Shares Outstanding54,395,714
10 Day Avg. Volume2,644
30 Day Avg. Volume6,074
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)1.29
Price to Sales (P/S)0.71
P/FCF Ratio83.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.37Price Target Upside-7.50% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$32.60M
ImExHS Limited Business Overview & Revenue Model
Company Description
ImExHS Limited delivers cloud-powered medical imaging technologies to customers worldwide, including those in Australia. The firm specializes in the development and sale of modular imaging software systems, which encompass comprehensive informatio...
ImExHS Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
74
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.26M | 28.97M | 26.57M | 19.67M | 17.12M | 13.37M |
| Gross Profit | 10.13M | 8.31M | 11.03M | 3.50M | 3.52M | 5.22M |
| EBITDA | 2.53M | 1.52M | 45.58K | -1.26M | -744.21K | -3.00M |
| Net Income | 188.61K | -2.88M | -2.63M | -4.19M | -3.04M | -4.70M |
Balance Sheet | ||||||
| Total Assets | 26.57M | 23.73M | 21.81M | 22.65M | 20.99M | 25.01M |
| Cash, Cash Equivalents and Short-Term Investments | 1.99M | 3.30M | 2.07M | 2.36M | 1.91M | 4.19M |
| Total Debt | 455.34K | 566.32K | 1.19M | 1.29M | 1.12M | 2.40M |
| Total Liabilities | 9.35M | 7.86M | 7.33M | 6.67M | 5.09M | 8.36M |
| Stockholders Equity | 17.22M | 15.87M | 14.47M | 15.98M | 15.90M | 16.65M |
Cash Flow | ||||||
| Free Cash Flow | 1.28M | 244.16K | -1.69M | 414.59K | -4.23M | -5.53M |
| Operating Cash Flow | 1.49M | 564.71K | -634.68K | 2.61M | -2.20M | -2.97M |
| Investing Cash Flow | -1.18M | -1.19M | -765.91K | -2.13M | -2.22M | -3.39M |
| Financing Cash Flow | -1.10M | 1.68M | 1.18M | -98.61K | 2.25M | -161.78K |
ImExHS Limited Technical Analysis
Neutral
0.40
Price Trends
0.32
Positive
0.33
Negative
0.36
Negative
Market Momentum
>-0.01
Negative
51.48
Neutral
55.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IME, the sentiment is Neutral. The current price of 0.4 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.32, and above the 200-day MA of 0.36, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.48 is Neutral, neither overbought nor oversold. The STOCH value of 55.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:IME.
ImExHS Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$134.98M | 58.82 | 2.53% | ― | 26.61% | 41.67% | |
52 Neutral | AU$17.68M | 92.86 | 1.14% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$130.07M | -7.49 | -203.69% | ― | -1.53% | 28.29% | |
49 Neutral | AU$29.53M | -1.59 | -58.13% | ― | 2.08% | -195.31% | |
47 Neutral | AU$54.05M | -6.05 | -24.29% | ― | -17.35% | -47.29% | |
47 Neutral | AU$20.19M | -2.22 | -1688.04% | ― | 11.45% | 0.69% |
* Healthcare Sector Average
AU:IME
ImExHS Limited
0.33
0.07
25.00%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.16
-0.05
-26.19%
AU:M7T
Mach7 Technologies
0.23
-0.09
-28.13%
AU:BMT
Beamtree Holdings Ltd
0.10
-0.13
-56.52%
AU:ALC
Alcidion Group Limited
0.10
0.01
11.11%
AU:PCK
PainChek Ltd
0.10
-0.70
-87.98%
ImExHS Limited Corporate Events
ImExHS trims capital structure as over 260,000 options lapse
Sep 1, 2026
ImExHS Limited has notified the market of the cessation of several tranches of options, following a review of its issued capital. The affected securities include options expiring in 2034, 2035 and 2036, all with nil exercise price, that have now l...
ImExHS Delivers Strong 1H FY26 Growth as AI Radiology Platform Gains Traction
Aug 28, 2026
ImExHS reported a solid first half of FY26, with revenue rising 17% year-on-year to $16 million and underlying EBITDA improving to $1.3 million, while annualised recurring revenue climbed 12% to $36.8 million. Debt was reduced to $0.25 million, th...
ImExHS Posts Half-Year Profit Turnaround and Strengthens Asset Base
Aug 28, 2026
ImExHS Limited reported a strong improvement in its financial performance for the half-year ended 30 June 2026, with revenues from ordinary activities rising 16.8% to $15.95 million. The company achieved a turnaround to a post-tax profit of $66,20...
ImExHS Books Record Quarter as Mexico AI Deal Validates Workflow Strategy
Jul 31, 2026
ImExHS delivered another record quarter in Q2 FY26, posting revenue of $8.0 million, up 21% year on year, and lifting underlying EBITDA to $0.4 million, while first-half revenue reached $16 million and ARR rose 12% to $36.8 million. The balance sh...
IMEXHS Relocates Registered Office to New North Sydney Address
Jul 28, 2026
IMEXHS Limited has changed its registered office to new premises in North Sydney, reflecting an update to its official corporate address and contact details. While administrative in nature, the move may support the company’s ongoing operatio...
ImExHS appoints new company secretary following sudden resignation
Jul 28, 2026
ImExHS Limited has announced the immediate resignation of company secretary Reena Minhas, with the board expressing its appreciation for her service. The company has moved quickly to ensure continuity by appointing experienced governance professio...
ImExHS Lists Additional Ordinary Shares on ASX
Jul 6, 2026
ImExHS Limited has applied for quotation of 20,044 ordinary fully paid shares on the ASX, following the issue of new securities dated May 12, 2026. The additional shares, arising from the exercise or conversion of existing options or other convert...
ImExHS Director Damian Banks Restructures Shareholding Into Super Fund
Jul 6, 2026
ImExHS Limited has reported a change in director Damian Banks’ interests in the company’s securities, reflecting an internal restructuring of his shareholdings. The move involves the transfer of his directly held fully paid ordinary sh...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.